Published February 4, 2021 | Version v1
Dataset Restricted

Dataset related to article "Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA‐based urine test, in active surveillance (AS) patients with recurrent non‐muscle‐invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project"

Description

This record contains raw data related to article “ "Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA‐based urine test, in active surveillance (AS) patients with recurrent non‐muscle‐invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project""

 

The paper investigates the clinical performance of a new mRNA-based urine test, aiming to avoid unnecessary follow-up cystoscopy in patients under active surveillance (AS) for recurrent NMIBC. This is a prospective cohort study enrolling patients with history of low-grade (LG) NMIBC, who developed a recurrence during the follow-up and underwent AS. Their urinary samples were analyzed by Xpert BC Monitor (Cepheid, Sunnyvale, CA, USA). The primary endpoint was to investigate if Xpert BC Monitor could avoid unnecessary cystoscopy during the follow-up period. Its sensitivity, specificity, PPVs and NPVs were calculated. A cutoff of 0.4 “linear discriminant analysis” (LDA) was optimized for the AS setting. The cohort consisted of 106 patients with a mean age of 72±9.52 and a median follow-up from AS start of 8.8 (range 0–56.5) months. No statistically significant difference was found for the mean age, smoker status, lesion size, and number of lesions with a cutoff of 0.4. Of 106 patients, 22 (20.8%) were deemed to require treatment because of cystoscopic changes in size and/or number of lesions during the follow-up period. Using a cutoff value of < 0.4, 34 (33.7%) cystoscopies could be avoided due to low LDA value, missing 2/22 (9%) failures, none with high-grade (HG) NMIBC. Further research on larger population remains mandatory before its clinical use.Xpert BC Monitor seems to be a reliable assay, which might avoid unnecessary cystoscopies without missing HG NMIBC when its cutoff is optimized for the AS setting.

Files

Restricted

The record is publicly accessible, but files are restricted. Log in to check if you have access.

Request access

If you would like to request access to these files, please fill out the form below.

You need to satisfy these conditions in order for this request to be accepted:

biblio

You are currently not logged in. Do you have an account? Log in here

Additional details

Related works

Is supplement to
10.1007/s00345-019-03002-3 (DOI)
31691083 (PMID)